Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Primary Target

DNA-(apurinic or apyrimidinic site) lyase

8

Histamine H1 receptor

315

Dopamine D2 receptor

297

DNA

278

Bacterial penicillin-binding protein

233

All Match

Any Match

Exclude Selected

Exclude Selected

Development Status

Investigational

4

Other

2

US Previously Marketed

2

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Phase II

4

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

Unknown

6

1960

2

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Cancer

4

Schistosomiasis

4

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Curative

4

Primary

4

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Sterling Drug

4

Dr. Mauss

2

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

8

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

8

FDA UNII

8

PUBCHEM

8

EPA CompTox

7

ChEMBL

4

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Salts, Hydrates, Esters, etc.

5

Principal Form

3

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 8 of 8 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

HYCANTHONE

2BXX5EVN2A

Export Data
Search for Structure

Status:

Investigational

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

monoamine oxidase activity

DNA-(apurinic or apyrimidinic site) lyase

UniProtKB: Q71SU7 (Carboxylic ester hydrolase)

Conditions:

Schistosomiasis

Hycanthone is a thioxanthene derivative of lucanthone with anti-schistosomal activity and potential antineoplastic activity. It was clinically available for the treatment of human schistosomiasis. Anti-helmintic action relies on its ability to inhibi...

t worm monoamine oxidase and cholinesterases. Hycanthone produced immediate side effects such as hepatotoxicity and gastrointestinal disturbances, and was consequently withdrawn. Hycanthone inhibits apurinic endonuclease-1 (APE1) by direct protein binding. Hycanthone was used in the 1980s as antitumor agents, it was pulled out of Phase II trials.

6-HYDROXYDOPA, DL-

9HBL9XYQ8O

Export Data
Search for Structure

Status:

Other

Class (Stereo):

CHEMICAL (RACEMIC)

Targets:

DNA-(apurinic or apyrimidinic site) lyase

DNA repair protein RAD52 homolog

LUCANTHONE

FC6D57000M

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 1960

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

DNA topoisomerase II alpha

DNA-(apurinic or apyrimidinic site) lyase

Lucanthone is a thioxanthenone DNA intercalator. It inhibits topoisomerases and the dual function base excision repair enzyme apurinic endonuclease 1. Lucanthone has been devised for the treatment of schistosomiasis. It is also an antitumor agent. Lu...

canthone was being developed by Spectrum Pharmaceuticals for the treatment of malignant brain tumours.

HYCANTHONE MESYLATE

48830NW22A

Export Data
Search for Structure

Status:

Investigational

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

monoamine oxidase activity

DNA-(apurinic or apyrimidinic site) lyase

UniProtKB: Q71SU7 (Carboxylic ester hydrolase)

Conditions:

Schistosomiasis

Hycanthone is a thioxanthene derivative of lucanthone with anti-schistosomal activity and potential antineoplastic activity. It was clinically available for the treatment of human schistosomiasis. Anti-helmintic action relies on its ability to inhibi...

t worm monoamine oxidase and cholinesterases. Hycanthone produced immediate side effects such as hepatotoxicity and gastrointestinal disturbances, and was consequently withdrawn. Hycanthone inhibits apurinic endonuclease-1 (APE1) by direct protein binding. Hycanthone was used in the 1980s as antitumor agents, it was pulled out of Phase II trials.

HYCANTHONE ETHANESULFONATE

IOB67KGQ3N

Export Data
Search for Structure

Status:

Investigational

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

monoamine oxidase activity

DNA-(apurinic or apyrimidinic site) lyase

UniProtKB: Q71SU7 (Carboxylic ester hydrolase)

Conditions:

Schistosomiasis

Hycanthone is a thioxanthene derivative of lucanthone with anti-schistosomal activity and potential antineoplastic activity. It was clinically available for the treatment of human schistosomiasis. Anti-helmintic action relies on its ability to inhibi...

t worm monoamine oxidase and cholinesterases. Hycanthone produced immediate side effects such as hepatotoxicity and gastrointestinal disturbances, and was consequently withdrawn. Hycanthone inhibits apurinic endonuclease-1 (APE1) by direct protein binding. Hycanthone was used in the 1980s as antitumor agents, it was pulled out of Phase II trials.

HYCANTHONE SULFAMATE

6QS8DNR44V

Export Data
Search for Structure

Status:

Investigational

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

monoamine oxidase activity

DNA-(apurinic or apyrimidinic site) lyase

UniProtKB: Q71SU7 (Carboxylic ester hydrolase)

Conditions:

Schistosomiasis

Hycanthone is a thioxanthene derivative of lucanthone with anti-schistosomal activity and potential antineoplastic activity. It was clinically available for the treatment of human schistosomiasis. Anti-helmintic action relies on its ability to inhibi...

t worm monoamine oxidase and cholinesterases. Hycanthone produced immediate side effects such as hepatotoxicity and gastrointestinal disturbances, and was consequently withdrawn. Hycanthone inhibits apurinic endonuclease-1 (APE1) by direct protein binding. Hycanthone was used in the 1980s as antitumor agents, it was pulled out of Phase II trials.

6-Hydroxydopa hydrochloride , DL-

FQJ6LEK5R9

Export Data
Search for Structure

Status:

Other

Class (Stereo):

CHEMICAL (RACEMIC)

Targets:

DNA-(apurinic or apyrimidinic site) lyase

DNA repair protein RAD52 homolog

LUCANTHONE HYDROCHLORIDE

918K9N56QZ

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 1960

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

DNA topoisomerase II alpha

DNA-(apurinic or apyrimidinic site) lyase

Lucanthone is a thioxanthenone DNA intercalator. It inhibits topoisomerases and the dual function base excision repair enzyme apurinic endonuclease 1. Lucanthone has been devised for the treatment of schistosomiasis. It is also an antitumor agent. Lu...

canthone was being developed by Spectrum Pharmaceuticals for the treatment of malignant brain tumours.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1